gabexate has been researched along with Coronary Heart Disease in 2 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ranucci, M | 1 |
| Chihara, K | 1 |
| Akiyama, F | 1 |
| Shinozaki, T | 1 |
| Shimamoto, M | 1 |
| Takahashi, K | 1 |
| Imura, H | 1 |
| Yamazaki, F | 1 |
| Kawarazaki, S | 1 |
2 other studies available for gabexate and Coronary Heart Disease
| Article | Year |
|---|---|
Gabexate mesilate and heparin responsiveness in coronary patients.
Topics: Aged; Antithrombins; Bleeding Time; Blood Coagulation; Coronary Disease; Factor Xa Inhibitors; Femal | 2004 |
[Disseminated intravascular coagulation (DIC) following open heart surgery and great vessel surgery. The result of early administration of gabexate mesilate (FOY)].
Topics: Adolescent; Adult; Aged; Blood Transfusion; Cardiac Surgical Procedures; Coronary Disease; Dissemina | 1984 |